Clinical trials: Tumors, Breast
Advanced Solid Tumors
Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone
The purpose of this study is to compare the pharmacokinetics of trifluorothymidine (FTD) as a component of TAS-102 with FTD alone.
- Trial name
- NCT01867866
- Testing
- TAS-102, Trifluridine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Taiho Oncology, Inc.
Breast Cancer
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth…
- Trial name
- NCT03084237
- Testing
- HLX02, Herceptin®, docetaxel
- Where
- 88 sites in China, Philippines and 1 more
- Volunteers
- 652 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Breast Cancer, Triple Negative Breast Cancer
cMet CAR RNA T Cells Targeting Breast Cancer
An open-label, clinical trial of autologous cMet redirected T cells administered intratumorally (IT) in patients with breast cancer. Fifteen evaluable patients will be enrolled in stepwise fashion.
- Trial name
- NCT01837602
- Testing
- cMet RNA CAR T cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
Breast Neoplasms, Neoplasm Metastasis
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
This study is a prospective, multicenter, phase II randomized clinical trial. It is planned to enroll 60 patients with advanced HER2 negative breast cancer, who will be randomly assigned to the experimental group and the control…
- Conditions
- Breast Neoplasms, Neoplasm Metastasis, Drug Therapy, Bevacizumab
- Trial name
- NCT06539559
- Testing
- Eribulin, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Wang Jiayu
Breast Cancer
OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment
Breast cancer management integrating surgery, systemic therapy and radiation therapy tends to systemic treatment as the first therapeutic option, continuing afterwards by surgery and radiation therapy with the scope of decreasing…
- Trial name
- OPTIMALIIa (NCT03972696)
- Testing
- Irradiation
- Where
- 20 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Grupo de Investigación Clínica en Oncología Radioterapia
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult…
- Conditions
- Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
- Trial name
- NCT07361562
- Testing
- CGT4255
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cogent Biosciences, Inc.
Peripheral Neuropathy
Acupuncture in Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer
The main purpose of this study is to define whether acupuncture in addition to the treatment of physician choice as per standard of care leads to a greater decrease of neuropathic pain as perceived by women with breast cancer who…
- Trial name
- Acu-CIPN (NCT05673746)
- Testing
- Acupuncture, treatment of physician choice, according to the standard of care
- Where
- 2 sites in Italy
- Volunteers
- 102 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer
A Phase II Study of Triple-negative Breast Cancer Brain Metastases.
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
- Trial name
- NCT04303988
- Testing
- SHR-1316, Bevacizumab, Cisplatin/Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fudan University
Breast Cancer, Vascular Disease，Peripheral
Onco-Vascular Exer-Study
In Chile, in the year 2022, the main causes of death were diseases of the circulatory system (31,606) and cancer (with 28,453 deaths).
- Conditions
- Breast Cancer, Vascular Disease，Peripheral, Arterial Hypertension, Endothelial Dysfunction
- Trial name
- NCT06766903
- Testing
- Exercise training
- Where
- Chile
- Volunteers
- 30 people
- Sponsor
- Cristian Alvarez
Cancer Related Cognitive Impairment, Breast Cancer Survivors
Cognitive Impairment Assessment in Breast Cancer Survivors
This study is a monocentric, observational, cross-sectional study with a case-control design, aimed at evaluating the construct validity, discriminative ability, and diagnostic accuracy of a second-level neuropsychological test…
- Trial name
- NCT07582770
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Breast Cancer Diagnosis, Breast Cancer Screening
A Comparative Study of Mammography and Ultrasound for Breast Cancer Screening and Early Diagnosis
Improving the early diagnosis of breast cancer can reduce mortality. With mammography as the main tool for screening early breast cancer, the characteristics of dense breast and young onset of disease in Chinese women lowers the…
- Trial name
- MUSD (NCT04429269)
- Testing
- mammography and ultrasound screening
- Where
- China
- Volunteers
- 6,000 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer
De-escalation of RNI in Breast Cancer Patients With pN0 After Neoadjuvant Therapy
Prospective Comparative Study of Response-Adapted De-escalation of Regional Nodal Irradiation in Initially Node Positive Breast Cancer Patients with Pathological Nodal Complete Response After Neoadjuvant Therapy
- Trial name
- OMIT-RNI (NCT07724769)
- Testing
- Adjuvant Radiotherapy
- Volunteers
- 100 people
- Sponsor
- Aya Ahmed Sayed
Breast Cancer
Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence
STUDY DESCRIPTION: This is a single-arm study to assess the feasibility, toxicity and cosmetic outcome of partial radiotherapy of the chest wall in breast cancer patients at increased risk of local relapse submitted to…
- Trial name
- NCT03101683
- Testing
- Partial chest wall radiation therapy
- Volunteers
- 28 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Breast Cancer
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined.
- Trial name
- NCT00191854
- Testing
- gemcitabine, paclitaxel, carboplatin
- Where
- 18 sites in Brazil, China and 4 more
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT)
A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
This study is a prospective clinical study enrolling breast cancer patients at high risk of chemotherapy-induced thrombocytopenia (CTIT).
- Trial name
- PROTECT (NCT07647029)
- Testing
- Continuous Hetrombopag for 2 Cycles, Cyclic 14-day Hetrombopag for 2 Cycles
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Fudan University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Swebcg 91:A RT. Breast Conserving Surgery With or Without Radiotherapy for Breast Cancer Patients
The main goal of the trial was to analyse the value of radiotherapy after breast conserving surgery for patients with breast cancer, and to find groups of patients where the treatment could be omitted.
- Trial name
- NCT06637202
- Testing
- postoperative radiotherapy
- Where
- Sweden
- Volunteers
- 1,187 people
- Sponsor
- Region Skane
Breast Cancer
APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
This study will compare the anti-tumor efficacy of apricoxib and lapatinib/capecitabine with placebo and lapatinib/capecitabine as measured by time to disease progression and evaluate urinary PGE-M measurements or baseline COX-2…
- Trial name
- APRiCOT-B (NCT00657137)
- Testing
- apricoxib + lapatinib + capecitabine
- Where
- 44 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tragara Pharmaceuticals, Inc.
Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
This is a single arm, open-label, phase I dose finding study, followed by a phase II expansion study. Phase I will be carried out in a modified 3+3 dose escalation design, with a projected enrolment of 33 patients with refractory…
- Conditions
- Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
- Trial name
- NCT05035745
- Testing
- Talazoparib, Selinexor
- Where
- Singapore
- Volunteers
- 63 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer, Stress
Stress Management in Breast Cancer Patients
The purpose of this study within Caring sciences is to identify women with breast cancer who have stress symptoms and to offer these women appropriate care to reduce stress and increase well-being. This will be achieved by 1.
- Trial name
- NCT01555645
- Testing
- Stress management, in two steps
- Where
- 3 sites in Sweden
- Volunteers
- 466 people
- Sponsor
- Uppsala University
Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB
Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer
Our study evaluates the use of Laser-Assisted Immunotherapy (LIT) plus placebo and LIT plus low-dose cyclophosphamide versus that of Standard of Care in patients presenting with Stage IIIA, IIIB or IV breast cancer.
- Conditions
- Breast Cancer Stage IIIA, Breast Cancer, Stage IIIB, Breast Cancer Stage IV
- Trial name
- NCT03202446
- Testing
- 1% Glycated Chitosan, Photothermal Laser, Cyclophosphamide
- Where
- 4 sites in Peru
- Volunteers
- 18 people
- Sponsor
- Eske Corporation S.A.C
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.